Molecular pharmacological profile of a novel thiazolinone-based direct and selective 5-lipoxygenase inhibitor

British Journal of Pharmacology

Volumn 165, Issue 7, 2012, Pages 2304-2313

  Hofmann, B ^a   Rodl C B ^a   Kahnt, A S ^a   Maier, T J ^a   Michel, A A ^a   Hoffmann, M ^a   Rau, O ^a   Awwad, K ^a   Pellowska, M ^a   Wurglics, M ^a   Wacker, M ^a   Zivkovic A ^a   Fleming, I ^a   Schubert Zsilavecz, M ^a   Stark, H ^a   Schneider, G ^a   Steinhilber, D ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

5 lipoxygenase; asthma; inflammation; leukotrienes; polymorphonuclear leukocytes; virtual screening

Indexed keywords

5 (4 METHOXYBENZYLIDENE) 2 (4 TOLYL) 5H THIAZOL 4 ONE; ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 15 LIPOXYGENASE; ARACHIDONATE 15 LIPOXYGENASE 1; ARACHIDONATE 15 LIPOXYGENASE 2; ARACHIDONATE 5 LIPOXYGENASE; CYCLOOXYGENASE 2; LIPOXYGENASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHOSPHOLIPASE A2; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL CELL; ARTICLE; BINDING SITE; CELL FREE SYSTEM; CELL VIABILITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; NEUTROPHIL; NONHUMAN; OXIDATION REDUCTION STATE; PRIORITY JOURNAL; RAT;

EID: 84858216778     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01707.x     Document Type: Article

References (48)

1. Albert D, Zündorf I, Dingermann T, Müller WE, Steinhilber D, Werz O, (2002). Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase. Biochem Pharmacol 64: 1767-1775. (Pubitemid 35355728)
2. Alexander SPH, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th Edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
3. Carter GW, Young PR, Albert DH, Bouska J, Dyer R, Bell RL, et al,. (1991). 5-lipoxygenase inhibitory activity of zileuton. J Pharmacol Exp Ther 256: 929-937.
4. Chen XS, Funk CD, (2001). The N-terminal 'beta-barrel' domain of 5-lipoxygenase is essential for nuclear membrane translocation. J Biol Chem 276: 811-818. (Pubitemid 32050382)
5. Chen Y, Hu Y, Zhang H, Peng C, Li S, (2009). Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat Genet 41: 783-792.
6. Derksen S, Rau O, Schneider P, Schubert-Zsilavecz M, Schneider G, (2006). Virtual screening for PPAR modulators using a probabilistic neural network. ChemMedChem 1: 1346-1350.
7. 2+ mobilization and functional leukocyte responses by hyperforin. Biochem Pharmacol 67: 1531-1539. (Pubitemid 38388215)
8. Feisst C, Pergola C, Rakonjac M, Rossi A, Koeberle A, Dodt G, et al,. (2009). Hyperforin is a novel type of 5-lipoxygenase inhibitor with high efficacy in vivo. Cell Mol Life Sci 66: 2759-2771.
9. Fischer AS, Metzner J, Steinbrink SD, Ulrich S, Angioni C, Geisslinger G, et al,. (2010). 5-Lipoxygenase inhibitors induce potent anti-proliferative and cytotoxic effects in human tumour cells independently of suppression of 5-lipoxygenase activity. Br J Pharmacol 161: 936-949.
10. Fischer L, Szellas D, RAdmark O, Steinhilber D, Werz O, (2003). Phosphorylation- and stimulus-dependent inhibition of cellular 5-lipoxygenase activity by nonredox-type inhibitors. FASEB J 17: 949-951.
11. Flamand N, Luo M, Peters-Golden M, Brock TG, (2009). Phosphorylation of serine 271 on 5-lipoxygenase and its role in nuclear export. J Biol Chem 284: 306-313.
12. Ford-Hutchinson AW, Gresser M, Young RN, (1994). 5-Lipoxygenase. Annu Rev Biochem 63: 383-417. (Pubitemid 24218638)
13. Geronikaki AA, Lagunin AA, Hadjipavlou-Litina DI, Eleftheriou PT, Filimonov DA, Poroikov VV, et al,. (2008). Computer-aided discovery of anti-inflammatory thiazolidinones with dual cyclooxygenase/lipoxygenase inhibition. J Med Chem 51: 1601-1609. (Pubitemid 351438844)
14. Gilbert NC, Bartlett SG, Waight MT, Neau DB, Boeglin WE, Brash AR, et al,. (2011). The structure of human 5-lipoxygenase. Science 331: 217-219.
15. Hammarberg T, Zhang YY, Lind B, Radmark O, Samuelsson B, (1995). Mutations at the C-terminal isoleucine and other potential iron ligands of 5-lipoxygenase. Eur J Biochem 230: 401-407.
16. Hammarberg T, Provost P, Persson B, RÃ¥dmark O, (2000). The N-terminal domain of 5-lipoxygenase binds calcium and mediates calcium stimulation of enzyme activity. J Biol Chem 275: 38787-38793. (Pubitemid 32009215)
17. 2+-independent arachidonic acid release in human platelets by facilitating cytosolic phospholipase A(2) activation through select phospholipid interactions. Biochim Biophys Acta 1801: 462-472.
18. Hofmann B, Franke L, Proschak E, Tanrikulu Y, Schneider P, Steinhilber D, et al,. (2008). Scaffold-hopping cascade yields potent inhibitors of 5-lipoxygenase. ChemMedChem 3: 1535-1538.
19. Hofmann B, Barzen S, Rödl CB, Kiehl A, Borig J, Ž ivković A, et al,. (2011). A class of 5-benzylidene-2-phenylthiazolinones with high potency as direct 5-lipoxygenase inhibitors. J Med Chem 54: 1943-1947.
20. Hörnig C, Albert D, Fischer L, Hörnig M, RÃ¥dmark O, Steinhilber D, et al,. (2005). 1-Oleoyl-2-acetylglycerol stimulates 5-lipoxygenase activity via a putative (phospho)lipid binding site within the N-terminal C2-like domain. J Biol Chem 280: 26913-26921. (Pubitemid 41040726)
21. Kulkarni S, Das S, Funk CD, Murray D, Cho W, (2002). Molecular basis of the specific subcellular localization of the C2-like domain of 5-lipoxygenase. J Biol Chem 277: 13167-13174. (Pubitemid 34952687)
22. Lang PA, Kasinathan RS, Brand VB, Duranton C, Lang C, Koka S, et al,. (2009). Accelerated clearance of plasmodium-infected erythrocytes in sickle cell trait and annexin-A7 deficiency. Cell Physiol Biochem 24: 415-428.
23. Mandal AK, Jones PB, Bair AM, Christmas P, Miller D, Yamin TT, et al,. (2008). The nuclear membrane organization of leukotriene synthesis. Proc Natl Acad Sci U S A 105: 20434-20439.
24. McMillan RM, Walker ER, (1992). Designing therapeutically effective 5-lipoxygenase inhibitors. Trends Pharmacol Sci 13: 323-330.
25. Menna C, Olivieri F, Catalano A, Procopio A, (2010). Lipoxygenase inhibitors for cancer prevention: promises and risks. Curr Pharm Des 16: 725-733.
26. Michel AA, Steinhilber D, Werz O, (2008). Development of a method for expression and purification of the regulatory C2-like domain of human 5-lipoxygenase. Protein Expr Purif 59: 110-116.
27. Nasser SM, Bell GS, Hawksworth RJ, Spruce KE, MacMillan R, Williams AJ, et al,. (1994). Effect of the 5-lipoxygenase inhibitor ZD2138 on allergen-induced early and late asthmatic responses. Thorax 49: 743-748. (Pubitemid 24250229)
28. Peters-Golden M, Henderson WR Jr, (2007). Leukotrienes. N Engl J Med 357: 1841-1854.
29. Purdon AD, Smith JB, (1985). Turnover of arachidonic acid in the major diacyl and ether phospholipids of human platelets. J Biol Chem 260: 12700-12704. (Pubitemid 16230557)
30. Purdon AD, Patelunas D, Smith JB, (1987). Evidence for the release of arachidonic acid through the selective action of phospholipase A2 in thrombin-stimulated human platelets. Biochim Biophys Acta 920: 205-214. (Pubitemid 17142894)
31. Radmark O, Samuelsson B, (2010). Microsomal prostaglandin E synthase-1 and 5-lipoxygenase: potential drug targets in cancer. J Intern Med 268: 5-14.
32. RÃ¥dmark O, Werz O, Steinhilber D, Samuelsson B, (2007). 5-Lipoxygenase: regulation of expression and enzyme activity. Trends Biochem Sci 32: 332-341. (Pubitemid 47021417)
33. Rai G, Kenyon V, Jadhav A, Schultz L, Armstrong M, Jameson JB, et al,. (2010). Discovery of potent and selective inhibitors of human reticulocyte 15-lipoxygenase-1. J Med Chem 53: 7392-7404.
34. Rödl CB, Tanrikulu Y, Wisniewska JM, Proschak E, Schneider G, Steinhilber D, et al,. (2011). Potent inhibitors of 5-lipoxygenase identified using pseudoreceptors. ChemMedChem 6: 1001-1005.
35. Romanov S, Wiesner R, Myagkova G, Kühn H, Ivanov I, (2006). Affinity labeling of the rabbit 12/15-lipoxygenase using azido derivatives of arachidonic acid. Biochemistry 45: 3554-3562.
36. Shumilina E, Kiedaisch V, Akkel A, Lang P, Hermle T, Kempe DS, et al,. (2006). Stimulation of suicidal erythrocyte death by lipoxygenase inhibitor Bay-Y5884. Cell Physiol Biochem 18: 233-242. (Pubitemid 44946978)
37. Turner CR, Smith WB, Andresen CJ, Eggler JF, Watson JW, (1996). The effect of 5-lipoxygenase inhibition on Ascaris antigen (Ag)-induced responses in atopic monkeys. Inflamm Res 45: 42-49. (Pubitemid 26032105)
38. Unangst PC, Connor DT, Cetenko WA, Sorenson RJ, Kostlan CR, Sircar JC, et al,. (1994). Synthesis and biological evaluation of 5-[[3,5-bis(1,1- dimethylethyl)-4-hydroxyphenyl]methylene]oxazoles,-thiazoles, and -imidazoles: novel dual 5-lipoxygenase and cyclooxygenase inhibitors with antiinflammatory activity. J Med Chem 37: 322-328. (Pubitemid 24063052)
39. Werz O, Steinhilber D, (2006). Therapeutic options for 5-lipoxygenase inhibitors. Pharmacol Ther 112: 701-718. (Pubitemid 44592614)
40. Werz O, Brungs M, Steinhilber D, (1996). Purification of transforming growth factor beta 1 from human platelets. Pharmazie 51: 893-896. (Pubitemid 26412712)
41. Werz O, Szellas D, Henseler M, Steinhilber D, (1998). Nonredox 5-lipoxygenase inhibitors require glutathione peroxidase for efficient inhibition of 5-lipoxygenase activity. Mol Pharmacol 54: 445-451. (Pubitemid 28368835)
42. Werz O, Bürkert E, Fischer L, Szellas D, Dishart D, Samuelsson B, et al,. (2002a). Extracellular signal-regulated kinases phosphorylate 5-lipoxygenase and stimulate 5-lipoxygenase product formation in leukocytes. FASEB J 16: 1441-1443.
43. Werz O, Szellas D, Steinhilber D, RÃ¥dmark O, (2002b). Arachidonic acid promotes phosphorylation of 5-lipoxygenase at Ser-271 by MAPK-activated protein kinase 2 (MK2). J Biol Chem 277: 14793-14800. (Pubitemid 34959961)
44. Werz O, Bürkert E, Samuelsson B, RÃ¥dmark O, Steinhilber D, (2002c). Activation of 5-lipoxygenase by cell stress is calcium independent in human polymorphonuclear leukocytes. Blood 99: 1044-1052. (Pubitemid 34527142)
45. Woods JW, Evans JF, Ethier D, Scott S, Vickers PJ, Hearn L, et al,. (1993). 5-Lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes. J Exp Med 178: 1935-1946. (Pubitemid 23344852)
46. Yoshimoto T, Yokoyama C, Ochi K, Yamamoto S, Maki Y, Ashida Y, et al,. (1982). 2,3,5-Trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone (AA861), a selective inhibitor of the 5-lipoxygenase reaction and the biosynthesis of slow-reacting substance of anaphylaxis. Biochim Biophys Acta 713: 470-473. (Pubitemid 13222960)
47. Zayed EM, Elbannany AAA, Ghozlan SAS, (1985). Studies on thiazolin-4-one: synthesis of some pyrano[2,3b]-thiazole derivatives. Pharmazie 40: 194-196. (Pubitemid 15124232)
48. Zhang YY, Radmark O, Samuelsson B, (1992). Mutagenesis of some conserved residues in human 5-lipoxygenase: effects on enzyme activity. Proc Natl Acad Sci U S A 89: 485-489.